Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

biomarkers

- PMLiVE

Lilly’s stomach cancer drug cleared by FDA

Cyramza is tipped to reach blockbuster status depending on approvals

- PMLiVE

BioAlliance and Topotarget merge to focus on rare cancers

French and Danish firms combine to develop orphan oncology drugs

- PMLiVE

UK cancer awards programme launches

QiC Oncology 2014  announced at ABPI Annual Conference

- PMLiVE

Glioblastomas – a personalised future?

Despite some recent advances treatment remains palliative

- PMLiVE

Lilly thrown a lifeline on US Alimta patent

Court backs protection from generics until 2022

- PMLiVE

GSK halts bid for Votrient maintenance use

Pulls European application for indication in advanced ovarian cancer

National Institute for Health and Care Excellence NICE logo

Boehringer cancer drug on course for NHS use in UK

NICE backs Giotrif in draft guidance

- PMLiVE

Roche appoints new oncology research head

William Pao leaves academia for pharma role

- PMLiVE

New data puts Jakafi on course for blockbuster status

Novartis/Incyte drug meets targets in blood cancer trial

- PMLiVE

NICE relents and backs Pfizer’s Inlyta

Recommends drug to treat advanced kidney cancer on NHS in England

Roche - Basel

Roche drug fails in lung cancer trial

Damages prospects for onartuzumab

- PMLiVE

Developing therapeutic cancer vaccines

Dendreon’s success has paved the way for new candidates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links